Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort

被引：0
作者：
Corentin Le Cacheux
Audrey Couturier
Clara Sortais
Roch Houot
Morgane Péré
Thomas Gastinne
Amélie Seguin
Jean Reignier
Jean-Baptiste Lascarrou
Jean-Marc Tadié
Quentin Quelven
Emmanuel Canet
机构：
[1] Centre Hospitalier Universitaire Hôtel-Dieu,Service de Médecine Intensive Réanimation
[2] Rennes University Hospital,Clinical Haematology Department
[3] Rennes University,Haematology Department
[4] Nantes University Hospital,Biostatistics Department
[5] Nantes University,ICU
[6] Nantes University Hospital,ICU
[7] Nantes University,undefined
[8] Nantes University,undefined
[9] Nantes University Hospital,undefined
[10] —Interactions—Performance Research Unit (MIP,undefined
[11] UR 4334),undefined
[12] Rennes University Hospital,undefined
[13] Rennes University,undefined
来源：
Annals of Intensive Care | / 14卷
关键词：
Chimeric antigen receptor T Cell; Intensive care unit; Cytokine release syndrome; Immune effector cell-associated neurotoxicity syndrome; Haemophagocytic lymphohistiocytosis; Sepsis; Mortality;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 193 条
[1]  
Bachmann M(2019)The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells Immunol Lett 211 13-22
[2]  
McGuirk J(2017)Building blocks for institutional preparation of CTL019 delivery Cytotherapy 19 1015-1024
[3]  
Waller EK(2019)Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma N Engl J Med 380 45-56
[4]  
Qayed M(2017)Axicabtagene ciloleucel CAR T-cell therapy in refractory Large B-cell lymphoma N Engl J Med 377 2531-2544
[5]  
Abhyankar S(2018)Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia N Engl J Med 378 439-448
[6]  
Ericson S(2019)Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma N Engl J Med 380 1726-1737
[7]  
Holman P(2021)Idecabtagene vicleucel in relapsed and refractory multiple myeloma N Engl J Med 384 705-716
[8]  
Schuster SJ(2022)Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma N Engl J Med 386 640-654
[9]  
Bishop MR(2018)The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review Ann Hematol 97 1327-1335
[10]  
Tam CS(2019)Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy Bone Marrow Transplant 54 780-784
12345678910